To test whether cDC1 supports or inhibits the progression of myeloma, we used a Vk*MYC myeloma mouse model that can be used to monitor the tumor based on CD155 and IgG2b expression, and the XCR1-DTR mouse line that can inductively deplete cDC1 in the body. This evidence concerns the gene PVR and plasma cell myeloma.